[6R] 5,10-methylenetetrahydrofolate (arfolitixorin)

DRUG2 trials

Sponsors

Isofol Medical AB

Conditions

OsteosarcomaRectal Cancer

Phase 1

An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer

CompletedNCT01397305

Isofol Medical ABRectal Cancer

Start: 2011-04-14End: 2014-10-16Updated: 2020-09-09

Investigation of [6R] 5,10-methylenetetrahydrofolate (Arfolitixorin) as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX.

CompletedNCT01987102

Isofol Medical ABOsteosarcoma

Start: 2013-12-31End: 2017-01-03Updated: 2020-09-25